A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Hormone Refractory Prostate Cancer
Interventions
BIOLOGICAL

Mycobacterium w.

Immunomodulator

DRUG

Docetaxel

Chemotherapeutic agent

Trial Locations (14)

110085

Rajiv Gandhi Cancer Institute & Research Center, Rohini

141008

Christian Medical College, Ludhiana, Ludhiana

144001

Patel Hospital Pvt. Ltd., Jalandhar

160012

Post Graduate Institute of Medical Education and Research, Chandigarh

334003

S.P. Medical College & A. G. of Hospitals, Bikaner

400012

Seth G.S. Medical College & KEM Hospital, Pārel

400022

Lokmanya Tilak Municipal Medical College & General Hospital, Sion

452014

Choithram Hospital & Research Centre, Indore

560029

Kidwai Memorial Institute of Oncology, Bangalore

576104

Kasturba Hospital,, Manipal

632002

Christian Medical College, Vellore

695011

Regional Cancer Centre, Trivandrum

Unknown

V.M. Medical College & Safdarjang Hospital, New Delhi

Chatrapati Sahuji Mahraj Medical University, Lucknow

Sponsors
All Listed Sponsors
lead

Cadila Pharnmaceuticals

INDUSTRY

NCT00525408 - A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter